MAR 2 2 2001

Patent Application Attorney Docket No.PCS10361ADAM

I hereby certify that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Hon. Director - U.S. Patent and Trademark Office, Washington, D.C. 20231 orthis 19 day of March, 2001

Janice M. Denison

(Typed or printed name of person)

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Lee Harland

**APPLICATION NO.: 09/684,725** Examiner: To Be Assigned

FILING DATE: Group Art Unit: 1646 10/06/2000

TITLE: Novel Polypeptide

Director - U.S. Patent and Trademark Office

Washington, D.C. 20231

RECEIVED

MAR 2 3 2001

Sir:

INFORMATION DISCLOSURE STATEMENT PURSUANT TO 37 C.F.R. § 1.97 ET SEQ.

TECH CENTER 1600/2900

Applicant herein make available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820 which lists the references cited by the applicant, copies of which are enclosed.

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a).

It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

Date: 3-19-01

Respectfully submitted,

Deborah A. Martin

Attorney for Applicant(s)

Reg. No. 44,222

Pfizer Inc.

Patent Department, MS 4159 Eastern Point Road Groton, Connecticut 06340 (860) 715-1821

INFORMATION DISCLOSURE STATEMENT, 9/99, (1/1)